Unclaimed brand
Learn about how ARTBIO is redefining cancer care through a new class of alpha radioligand therapies and building an ecosystem to maximize their potential.
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#D84192
Cerise
216, 65, 146
328, 66, 55
0, 70, 32, 15
#93CDE0
Morning Glory
147, 205, 224
195, 55, 73
34, 8, 0, 12
#553D81
Victoria
85, 61, 129
261, 36, 37
34, 53, 0, 49
ARTBIO is a biotechnology company focused on developing alpha radioligand therapies (ART) to advance cancer care. Its patient-centered approach combines cancer biology and targeted drug design with the infrastructure needed to produce and deliver therapies. The company aims to develop treatments that selectively target tumors while limiting harm to healthy tissue, and is building an ecosystem spanning isotope production, manufacturing, and distribution.
ARTBIO’s pipeline includes AB001, its lead program for prostate cancer, which has entered Phase 1 clinical studies. The company has also disclosed programs in development for triple-negative breast cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, pancreatic cancer, and multiple solid tumors; several targets remain undisclosed. Its approach includes the Pb-212 isotope and the company’s AlphaDirect isotope-production platform.
Founded in 2021, ARTBIO draws on scientific work originating at the University of Oslo and Norway’s Radium Hospital. Its founders helped develop Xofigo, an earlier targeted alpha therapy. ARTBIO brings together multidisciplinary expertise in research, clinical development, manufacturing, and operations to advance its therapies.
The ARTBIO name, logos and brand assets are trademarks of ARTBIO and its affiliates. Brandfetch isn't affiliated with or endorsed by ARTBIO. Their use is subject to ARTBIO's brand guidelines.
